Noninvasive prenatal screening (NIPS) that uses cell-free DNA (cfDNA) from the plasma of pregnant women offers tremendous potential as a screening method for fetal aneuploidy. ACOG and SMFM recommended it as a screening option for women at increased risk of aneuploidy such as AMA, or women with positive first or second trimester screening test results.